Contingency management to reduce cannabis use for patients with comorbidities

Reducing cannabis use for patients with comorbidities could improve clinical, cognitive, and psychosocial outcomes. Contingency management (CM) for patients with comorbid diagnoses was assessed in a narrative systematic review (Rodas et al., 2022, 6 studies, 4 focused on Schizophrenia and schizoaffective disorder, while the remaining two involved patients with major depressive disorder) and found to have an effect in:

• decreasing cannabis use.

More research is needed to establish the implications of CM for improving psychiatric symptoms in patients with comorbidities. Several studies in the current review did not find significant results in reducing psychiatric symptom severity.